Selection for Oncotype Dx testing among young women with early-stage ER+/HER2-breast cancer.

被引：3
|
作者：
Poorvu, Philip Daniel
Gelber, Shari I.
Rosenberg, Shoshana M.
Ruddy, Kathryn Jean
Tamimi, Rulla
Peppercorn, Jeffrey M.
Schapira, Lidia
Borges, Virginia F.
Come, Steven E.
Collins, Laura C.
Warner, Ellen
Partridge, Ann H.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin, Dept Oncol, Rochester, MN USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Stanford Canc Ctr, Palo Alto, CA USA
[6] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[7] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[8] Harvard Med Sch, Boston, MA USA
[9] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Replication of risk characterization in a cohort with women with advanced ER+/HER2-breast cancer using a new analytic tool
    Zhou, Xiaofeng
    de Luise, Cynthia
    Prince, Patricia
    Shen, Rongjun
    Luo, Kaiyi
    Louder, Anthony
    Gatto, Nicolle M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 66 - 67
  • [42] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah M.
    Liu, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Response of persistent metastatic ER+/Her2-breast cancer treated with fulvestrant plus enzalutamide
    Richer, Jennifer
    Spoelstra, Nicole
    Winchester, Alyse
    Wulfkuhlue, Julia
    Gallagher, Rosa
    Sams, Sharon
    Vidal, Gregory
    Kabos, Peter
    Diamond, Jennifer
    Shagisultanova, Elena
    Afghahi, Anosheh
    Mayordomo, Jose
    McSpadded, Tessa
    Crawford, Gloria
    Borges, Virginia
    Gao, Dexiang
    Petricoin, Emanuel
    Elias, Anthony
    CANCER RESEARCH, 2022, 82 (04)
  • [44] EVALUATION OF AROMATASE INHIBITOR UTILIZATION AND FAILURE IN POST-MENOPAUSAL WOMEN WITH ADVANCED ER+/HER2-BREAST CANCER
    Landsman-Blumberg, P.
    Namjoshi, M.
    Thomson, E.
    Johnson, W.
    VALUE IN HEALTH, 2012, 15 (04) : A229 - A230
  • [45] Comparison of oncological outcomes of premenopausal with ovarian function suppression versus postmenopausal women in ER+/HER2-breast cancer
    Lee, Min Jung
    Jung, Ji-Jung
    Cheun, Jong-Ho
    Kang, Eunhye
    Kim, Hong-Kyu
    Lee, Han-Byoel
    Moon, Hyeong-Gon
    Han, Wonshik
    BREAST, 2025, 81
  • [46] News on the medical treatment of young women with early-stage HER2-negative breast cancer
    Lambertini, Matteo
    Poggio, Francesca
    Vaglica, Marina
    Blondeaux, Eva
    Del Mastro, Lucia
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (12) : 1643 - 1655
  • [47] Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, Her2-breast cancer.
    Munster, Pamela N.
    Hamilton, Erika Paige
    Estevez, Laura G.
    De Boer, Richard H.
    Mayer, Ingrid A.
    Campone, Mario
    Asano, Shizuka
    Bhansali, Suraj
    Zhang, Vickie
    Hewes, Becker
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [48] Oncotype DX testing in early-stage node-positive breast cancer and impact on chemotherapy use at a comprehensive cancer center.
    Losk, Katya
    Freedman, Rachel A.
    Mittendorf, Elizabeth A.
    Tan-Wasielewski, Zhenying
    Trippa, Lorenzo
    King, Tari A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
    Su Hyun Lee
    Seunggyun Ha
    Hyun Joon An
    Jae Sung Lee
    Wonshik Han
    Seock-Ah Im
    Han Suk Ryu
    Won Hwa Kim
    Jung Min Chang
    Nariya Cho
    Woo Kyung Moon
    Gi Jeong Cheon
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1574 - 1584
  • [50] Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
    Lee, Su Hyun
    Ha, Seunggyun
    An, Hyun Joon
    Lee, Jae Sung
    Han, Wonshik
    Im, Seock-Ah
    Ryu, Han Suk
    Kim, Won Hwa
    Chang, Jung Min
    Cho, Nariya
    Moon, Woo Kyung
    Cheon, Gi Jeong
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (09) : 1574 - 1584
12345